Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

Ahead of the Bengals-Giants game on Sunday, Oct. 13, Jill joined the program to discuss her history with breast cancer and urge viewers to consider genetic testing if they're high risk — a step ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

“Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients ...

A vaccine against triple-negative breast cancer was found to produce an immune response and was well tolerated by most patients during an ongoing clinical trial. The findings will be presented by ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

Breast cancer rates rose by 1 percent per year from 2012-2021 for all U.S. women combined, with steeper increases for women under 50 and Asian American and Pacific Islander women, according to the ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

More than $500,000 was expected to be raised for the American Cancer Society. The walk is a celebration of courage and hope and a movement that unites communities to end breast cancer, according ...

A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...